Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues. 

Physicians now have the powerful imaging technology they need for fast, safe and reliable evaluation of liver lesions with the premium AplioTM i-series ultrasound platform from Toshiba Medical, a Canon Group company. 

Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation and more personalized care at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 Annual Meeting. 

ABS, one of the largest breast departments in the country, first signed with Insignia in 2010, and have confirmed a further 5 year managed service contract with PACS provider Insignia. 

Medica and Compmed Medical Technology Conference

World Federation of Nuclear Medicine and Biology

Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow edition, a cost-competitive positron emission tomography/computed tomography (PET/CT) system that features the company’s revolutionary FlowMotion continuous bed motion scanning technology.

The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy and radiosurgery option. MD Anderson will develop technologies to enhance and enable clinical implementation of CRnR’s X-ray lens system called Mercy Beam.

The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer today. While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new guideline addresses the appropriateness of SBRT for medically inoperable patients with high-risk clinical scenarios requiring curative focused therapy. 

The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic researchers to launch three add-on studies to expand the impact of the core study where more than 18,000 people with cognitive decline but an unclear diagnosis will receive an amyloid PET scan.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now